Evidence map›Paper›PMID 42879021›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Post-Translational Regulation Using Degrons in Ewing Sarcoma.

Florian H Geyer, Randolph K Larsen Iv, Florencia Cidre-Aranaz, David G McFadden

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Florian H Geyer *Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Randolph K Larsen Iv *Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Florencia Cidre-Aranaz *Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
David G McFadden *Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA. David.McFadden@UTSouthwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EWSR1::FLI1 (EF1) chimeric transcription factor is pathognomonic in Ewing Sarcoma (EwS) and is often the sole oncogenic mutation harbored by EwS tumors. Disrupting the function of EF1 to study its role in tumor biology using small molecules has proven challenging. Here, we describe complementary strategies to incorporate inducible protein degrons into the endogenous EWSR1::FLI1 locus in patient-derived EwS cells. These systems enable precise control over the timing and level of EF1 protein abundance as well as downstream functional analyses.

Indexed as

Oncogene Proteins, FusionProtein Processing, Post-TranslationalRNA-Binding Protein EWSSarcoma, EwingCell Line, TumorDegronsGene Expression Regulation, NeoplasticHumansProto-Oncogene Protein c-fli-1Oncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSAuxin-inducible degronEWSR1::FLI1Fusion oncoproteinHaloTagHiBiTInducible degronSmall molecule assisted shutoff

Identifiers

PMID42879021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.